Inhibrx Biosciences, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $74.18
- 52-Week Range
- $57.30 – $155.29
- Market Cap
- $1.02B
- P/E (TTM)
- —
- EPS (TTM)
- -9.06
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -39.51%
- Gross Margin
- 0.00%
- Operating Margin
- -6286.70%
- Profit Margin
- 0.00%
- Current Ratio
- 7.58
- Debt/Equity
- —
- Total Debt
- $281.44M
- Free Cash Flow
- $-81.11M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.10B
Market Snapshot
About
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology. The company's lead program targets alpha-fetoprotein (AFP)-positive tumors, including hepatocellular carcinoma, using a novel T cell engager platform. Inhibrx Biosciences leverages its proprietary single-domain antibody technology to create multi-specific therapeutics designed to redirect immune cells to tumor sites. The company's pipeline includes programs addressing difficult-to-treat solid tumors with high unmet medical needs.